Compare Adaptive Biotechnologies Corp (ADPT) vs Salesforce Inc (CRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Salesforce Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.03 (market cap $4.04B), while Salesforce Inc trades at $192.6 (market cap $161.73B). The key difference: Salesforce Inc is far larger — about 40× Adaptive Biotechnologies Corp's market cap, and Salesforce Inc pays a 0.89% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | CRM | |
|---|---|---|
Market Cap | $4.04B | $161.73B |
Sector | Health | Technology |
52-Week High | $25.45 | $266.23 |
52-Week Low | $12.30 | $150.12 |
Enterprise Value | $4.10B | $191.77B |
Dividend Yield | — | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
Salesforce (CRM) trades at $197.51, up 2.47% with strong technical momentum as the stock approaches resistance at $200. The company demonstrates robust fundamentals with consistent earnings beats, posting Q1 2026 EPS of $3.88 versus $3.13 expected, and maintains impressive profitability with 77.64% gross margins. Revenue growth accelerated to $37.9B in 2025 with net income reaching $6.2B, while analyst sentiment remains overwhelmingly positive with 76% buy ratings.
Outlook remains favorable with AI-driven growth catalysts and a $230.61 consensus price target offering 17% upside potential. Key risks include competitive pressures in the SaaS sector and market volatility from AI disruption concerns. The stock presents a compelling opportunity given its Rule of 44 performance metrics and strong cash flow generation of $13.1B from operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →
